AHA 2024 November 16–18, 2024

AHA 2024 November 16–18, 2024

The AHA Sessions 2024 were scheduled to be held from November 16th to 18th at the McCormick Place Convention Center in Chicago, IL. This event was brought together healthcare professionals, researchers, and experts from around the world to share and discuss the latest advancements and breakthroughs in cardiovascular science.

Triple Therapy: A New Era in Heart Health Management

Triple Therapy: A New Era in Heart Health Management

The study can provide useful information to interventional cardiologists performing PCI with new-generation DES in AMI patients, regarding the importance of hyperglycemia (especially prediabetes) and the relationship with worse cardiovascular outcomes after both high intensity and low-moderate-intensity statin treatment

Triple Therapy: A New Era in Heart Health Management

Timing Matters: How Irregular Meals Affect Diabetes Management

The study can provide useful information to interventional cardiologists performing PCI with new-generation DES in AMI patients, regarding the importance of hyperglycemia (especially prediabetes) and the relationship with worse cardiovascular outcomes after both high intensity and low-moderate-intensity statin treatment

Triple Therapy: A New Era in Heart Health Management

New Insights into Atrial Arrhythmias Following PFO Closure

The study can provide useful information to interventional cardiologists performing PCI with new-generation DES in AMI patients, regarding the importance of hyperglycemia (especially prediabetes) and the relationship with worse cardiovascular outcomes after both high intensity and low-moderate-intensity statin treatment

Triple Therapy: A New Era in Heart Health Management

Transforming Cardiovascular Health with Data-Driven Innovations

The study can provide useful information to interventional cardiologists performing PCI with new-generation DES in AMI patients, regarding the importance of hyperglycemia (especially prediabetes) and the relationship with worse cardiovascular outcomes after both high intensity and low-moderate-intensity statin treatment